LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced today that Dr. Kevin Rodan, its Chief Executive Officer, is expected to receive a Certificate of Excellence from the Ministry of Health. The recognition, scheduled to be presented on July 10, 2026, acknowledges Dr. Rodan's contributions to healthcare innovation, technological development, clinical practice, and healthcare advancement.
According to information provided to the Company, the award is part of Ministry of Health initiatives focused on recognizing healthcare professionals whose work supports innovation, medical technology development, and high standards of patient care. The Company believes this recognition reflects Dr. Rodan's commitment to advancing healthcare accessibility, digital health innovation, and responsible technology application within healthcare environments.
Management believes the recognition also underscores the growing importance of healthcare technology, digital infrastructure, and innovation-focused leadership in supporting the modernization of healthcare systems throughout Latin America. Dr. Rodan stated, 'I am honored to be recognized in connection with healthcare innovation and excellence. Healthcare systems throughout Latin America continue to face significant accessibility, coordination, and infrastructure challenges, and I believe technology can play an important role in helping address those challenges.'
The Certificate of Excellence is expected to be presented during an upcoming Ministry of Health event dedicated to recognizing contributions to healthcare advancement, innovation, and excellence within the healthcare sector. The Company noted that the recognition relates to Dr. Rodan's professional contributions and does not constitute a regulatory approval or endorsement of any specific product or commercial initiative.
LataMed AI Corp. focuses on building telehealth infrastructure, healthcare coordination tools, analytics capabilities, and AI-enabled solutions for emerging markets, with an initial regional focus on Latin America. For additional information, visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
